PHARMA MAR, S.A. «12345...» Página 5 de 18 desde 01/07/1988 hasta 26/09/2024 31/01/2019 08:42 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Results from Helix clinical trial with Tivanisiran for the treatment of dry eye disease Número de registro: 274317 28/01/2019 19:45 PHARMA MAR, S.A. Transmissions and purchases of capital undertakings Mandate to sell Pharma Mar´s stake in its subsidiary Zelnova Zeltia. Número de registro: 274204 Relacionado con 223175 del 19/05/2015 (18:41) 24/01/2019 08:11 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks COMP, from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepsyre® for small-cell lung cáncer Número de registro: 274111 08/01/2019 17:50 PHARMA MAR, S.A. Liquidity contracts and specialists The Company reports details of the operations of the Liquidity Agreement between 01/10/2018 and 31/12/2018 Número de registro: 273581 11/12/2018 07:54 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks The Australian Regulatory Agency (TGA) has approved Aplidin® to treat multiple myeloma in combination with dexamethasone. Número de registro: 272345 14/11/2018 15:12 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks 100 patients have been already recruited in the Phase II clinical trial of lurbinectedin as a single agent in recurrent small cell lung cancer. Número de registro: 271525 30/10/2018 17:49 PHARMA MAR, S.A. Information on P&L The Company sends press release regarding the third quarter 2018 results. Número de registro: 271036 30/10/2018 17:43 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del tercer trimestre de 2018 Número de registro: 271032 26/10/2018 15:29 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks IDMC recommends that the Phase III trial with Zepsyre® in relapsed small-cell lung cancer patients should continue without any changes Número de registro: 270927 19/10/2018 08:11 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks 300 patients have been already recruited in the Phase III clinical trial HELIX for the treatment of the signs and symptoms of dry eye disease. Número de registro: 270622 Página 5 de 18 «12345...»